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Summary
Increased expression of SIRT1 extends the lifespan of lower
organisms and delays the onset of age-related diseases in
mammals. Here, we show that SRT2104, a synthetic small
molecule activator of SIRT1, extends both mean and maximal
lifespan of mice fed a standard diet. This is accompanied by
improvements in health, including enhanced motor coordination,
performance, bone mineral density, and insulin sensitivity asso-
ciated with higher mitochondrial content and decreased inflam-
mation. Short-term SRT2104 treatment preserves bone and
muscle mass in an experimental model of atrophy. These results
demonstrate it is possible to design a small molecule that can
slow aging and delay multiple age-related diseases in mammals,
supporting the therapeutic potential of SIRT1 activators in
humans.
Key words: healthspan; inflammation; lifespan; muscle wast-
ing; osteoporosis; sirtuins.
Introduction
By 2050, there will be 1.5 billion people over the age of 65. This will
place a serious burden on global infrastructure and economy. As such,
there is an urgent need for treatment modalities to promote healthy
aging. The NAD+-dependent deacetylase SIRT1 represents an attractive
anti-aging target due to its ability to modulate various transcriptional and
metabolic pathways (Baur et al., 2012). Tissue-specific SIRT1 knock-
down in mice leads to pro-inflammatory and metabolic defects
(Purushotham et al., 2009; Price et al., 2012), and whole-body SIRT1
over-expression improves high-fat diet (HFD)-induced metabolic distur-
bances (Bordone et al., 2007; Gillum et al., 2011; Li et al., 2011)
without a beneficial effect on lifespan (Herranz et al., 2010). Despite
having many cellular targets (Pacholec et al., 2010), resveratrol (RSV), a
natural polyphenolic SIRT1 activator (Hubbard et al., 2013), improves
whole-body physiology and lifespan of mice on HFD (Baur et al., 2006;
Barger et al., 2008; Pearson et al., 2008) and also has benefits in obese
humans (Timmers et al., 2011). Synthetic SIRT1 activators with improved
selectivity for SIRT1 (Hubbard et al., 2013), such as SRT2104, increase
insulin sensitivity (Milne et al., 2007) and are well tolerated in healthy
adults (Hoffmann et al., 2013) and elderly volunteers (Libri et al., 2012).
Small but significant improvements in plasma lipid profiles (Venkata-
subramanian et al., 2013) and potential for improved insulin sensitivity
(Libri et al., 2012) have been reported with SRT2104 supplementation.
However, these studies are limited by their short treatment time. In this
study, the effect of SRT2104 supplementation on health and lifespan in
mice on a standard diet was investigated. The health benefits conferred
by SRT2104 led us to determine whether short-term treatment could
offer protection against disuse atrophy of muscle and bone that occurs
in an experimental model of prolonged immobility. Our results suggest
that interventions aimed at modulating SIRT1 activity via pharmacolog-
ical means could represent attractive approaches for delaying the onset
of aging and the development of age-related diseases, including
sarcopenia and osteoporosis.
Results and discussion
SRT2104 treatment improves whole-body physiology and
extends lifespan in mice fed a standard diet
To test the effects of the proprietary compound SRT2104, 6-month-old
male C57BL/6J mice were placed on a standard AIN-93G diet (SD)
supplemented with SRT2104 (100 mg kg1 bodyweight) for the
remainder of their lives, which yielded serum concentrations of
261.8  27.0 and 435.7  75.6 ng mL1 in the morning and evening,
respectively. SRT2104 supplementation resulted in improved survival of
SD-fed mice (v2 = 6.19 and P < 0.013) with an increase in mean lifespan
of 9.7% (P < 0.05) and in maximum lifespan (defined as the 10th
percentile) of 4.9% (P < 0.001) (Fig. 1A). The immunosuppressant
rapamycin has been recently shown to extend maximum lifespan of
genetically heterogeneous male mice (Miller et al., 2011), and when
started at 19 months of age, it also extends lifespan of male and female
C57BL/6Nia mice (Zhang et al., 2014). Moreover, oral supplementation
with the antidiabetic drug metformin leads to healthier and longer life in
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male mice (Martin-Montalvo et al., 2013). The incidences of major
pathologies detected at necropsy were reduced with SRT2104 treat-
ment, most notably a trend toward lower prevalence of an enlarged
heart and hepatocellular carcinoma with SRT2104, and a significant
reduction in peri-renal fat (Table S1, Supporting information). Blinded
histological analysis of tissues did not identify any serious pathology in
SD mice, and there were no obvious differences between the two groups
(Table S2). Consistent with this, biomarkers of liver injury or tissue
breakdown were reduced or unchanged after SRT2104 supplementation
(Table S3), further confirming that the dose was well tolerated with no
obvious toxicity. Interestingly, the increases in longevity induced by
SRT2104 occurred despite similar bodyweights between SD-fed controls
and treated animals (Fig. 1B). A reduction in percentage fat mass, but
not lean body mass, was observed in SRT2104-treated mice (Fig. 1C and
Table S4) despite no differences in food consumption (Figs 1D and S1A,
Supporting information). Moreover, SRT2104 treatment did not affect
spontaneous activity (Fig. 1E), energy expenditure (Fig. S1B), or respira-
tory exchange ratio (RER) of mice (Fig. S1C). Together, these data
indicate that the effects of SRT2104 on lifespan are not due to reduced
caloric intake or an increase in voluntary activity. Interestingly, our
findings of improved healthspan and modest increases in lifespan are in
contrast to whole-body overexpression of SIRT1, which has been shown
to result in improvements in healthspan without affecting the longevity
of transgenic mice (Herranz et al., 2010). It was recently reported that
Sirt1 activity in the dorsomedial and lateral hypothalamic nuclei (known
as DMH and LH regions) appears to delay aging and promote longevity in
both male and female mice (Satoh et al., 2013). It is tempting to
speculate that some of the beneficial effects of SRT2104 on maximum
lifespan stem from its ability to activate SIRT1 present in the DMH and LH
hypothalamic regions. Moreover, SRT2104 supplementation was started
at 6 months of age, and it is unclear whether treatment at a much
younger age would offer similar extension in mouse lifespan. Additional
experiments will be required to adequately address these issues. The
quality of life of SD-fed mice treated with SRT2104was then ascertained by
(A)
(D) (E) (F)
(H) (I) (J)
(K) (L) (M)
(G)
(B) (C)
Fig. 1 SRT2104 treatment improves whole-body physiology and extends lifespan in mice fed a standard diet. (A) Kaplan–Meier survival curves of mice fed a standard diet
(SD) or a SD supplemented with SRT2104. The arrow at 28 weeks indicates the age at which SRT2104 treatment was started. (B–M) The following parameters were analyzed
in SD-fed mice without and with SRT2104 supplementation: (B) bodyweights; (C) percentage fat mass; (D) average caloric intake; (E) spontaneous locomotor activity; (F)
treadmill performance; (G) time to fall from an accelerating rotarod; (H) trabecular bone volume; (I) trabecular connectivity; (J) trabecular bone mineral density (BMD); (K)
circulating glucose and (L) insulin levels were measured after 16 h of fasting; (M) homeostatic measure of insulin resistance (HOMA-IR) index. Data are shown as
mean  SEM. *P < 0.05 compared with SD-fed animals. BV, bone volume; TV, total volume; Tb, trabecular.
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monitoring muscle function, balance, and motor coordination. Mice
supplemented with SRT2104 exhibited significant improvement in endur-
ance performance on the treadmill (Fig. 1F) and better motor skills, as
assessed by rotarod performance (Fig. 1G).
Bone health was also assessed as osteoporosis leads to increased rates
of morbidity and mortality in the elderly due to a decrease in bone
strength and increased risk of fractures (Gass & Dawson-Hughes, 2006;
Lyles et al., 2007). In the distal femur of adult mice, SRT2104
significantly improved trabecular bone volume, trabecular connectivity,
and trabecular bone mineral density compared with control SD-fed
animals (Fig. 1H–J); however, no effect in cortical thickness was
observed (data not shown). Overall, SRT2104 improved a number of
parameters involved in bone health and suggests that SRT2104 may be a
countermeasure for age-related bone loss.
One hallmark of the aging process is the impairment of glucose
homeostasis that leads to type 2 diabetes and cardiovascular diseases.
Therefore, we next explored the effect of SRT2104 on whole-body
metabolism in mice on SD. Fasting blood glucose and insulin levels, and
insulin resistance index, as determined by homeostasis model assessment
of insulin resistance (HOMA-IR), were all significantly reduced in
SRT2104-treated mice (Fig. 1K–M). Apparent improvements in the oral
glucose tolerance test (OGTT) and insulin tolerance test (ITT) with
SRT2104 did not reach statistical significance (Fig. S1D,E). It is likely that
clamp studies would have provided solid evidence of the beneficial
metabolic effects of SRT2104. SRT2104 supplementation was accom-
panied by a trend toward reduced serum free-fatty acid (FFA) levels with
no change in circulating triglycerides or total cholesterol levels (Table S3).
SIRT1 overexpression increases fatty acid beta-oxidation (Purushotham
et al., 2009), and it is likely that SRT2104 supplementation will also have
an impact on this pathway. While the increases in beta-oxidation
reported by Purushotham et al. (2009) stemmed from lentiviral infection
of primary hepatocytes from liver-specific SIRT1-KO mice with recombi-
nant SIRT1 (Fig. 1D), this experimental model was markedly different
than our use of wild-type mice fed a standard diet. Therefore, the
changes observed by Purushotham et al. (2009) may not be directly
translatable to our study. It is interesting to note that short-term
SRT2104 supplementation was associated with improved lipid profile in
healthy cigarette smokers (Venkatasubramanian et al., 2013), which is
consistent with our findings. Overall, our results show for the first time
that SRT2104 prolongs lifespan, improves whole-body metabolic
function, and delays the onset of age-related diseases in SD-fed male
mice.
SRT2104 treatment increases mitochondrial content and
suppresses the inflammatory response
To further gauge the molecular mechanisms by which SRT2104 improved
whole-body metabolism and survival in SD-fed mice, a whole-genome
microarray analysis was performed on liver and muscle tissues. Principal
component analysis (PCA) showed a distinct separation of both treatment
groups, with the effect more pronounced in the muscle tissue (Fig. 2A).
For both the liver and muscle, the largest changes induced by SRT2104
treatment are presented in Table S5, and the complete dataset is available
at http://www.ncbi.nlm.nih.gov/geo/. Notably, transcripts belonging to
the cytokine-induced STAT inhibitor (CIS) family were upregulated in the
liver [suppressor of cytokine signaling 2 (SOCS2)] and muscle [cytokine-
inducible SH2-containing protein (CISH)] of SRT2104-treated mice,
consistent with suppression of the inflammatory response. Moreover,
within the highest affected transcripts, an upregulation of albumin D-box
binding protein (DBP) gene was found across both tissues. Interestingly,
DBP is a clock-controlled gene, whose circadian expression is regulated by
SIRT1 (Nakahata et al., 2008). To further investigate the effect of
SRT2104 in modifying liver and skeletal muscle gene expression, we next
performed parametric analysis of gene-set enrichment (PAGE). Pathways
that were altered by SRT2104 supplementation are graphically repre-
sented in Fig. 2B and indicated that the transcriptional effect of SRT2104
was stronger in muscle than in liver. Downregulation occurred for the
large majority of the modified pathways in response to SRT2104, which
included gene sets such as ‘inflammation’ and ‘mitochondrial metabo-
lism’ (Fig. 2C). The interpretation of microarray data has benefited from
comparison with the effects of calorie restriction (CR). Among the top
twenty genes whose expression was modified by SRT2104, more than
70% (14/20) were responsive to CR in the liver but less than 40% (8/20) in
skeletal muscle (Table S5). The gene encoding Txnip, a negative regulator
of mTORC1-mediated protein translation (Jin et al., 2011), was upreg-
ulated in the liver of SRT2104- and CR-treated mice, whereas the hepatic
expression of Elovl3, encoding a condensing enzyme that provides
precursors for ceramide synthesis (Park et al., 2010), was significantly
lower in response to Sirt1 induction by SRT2104 or CR. Moreover, Cish
expression in the mouse muscle was upregulated by CR, with a Z-ratio of
11.58 (Table S5). There were 81 and 76 gene sets that were significantly
modified by SRT2104 and CR, respectively, in mouse liver when compared
to SD-fed animals. Of these, 39 gene sets were shared with the majority
(25/39) being downregulated by both interventions (Fig. 2D). Mouse
skeletal muscle had more than 158 and 90 gene sets that were
significantly affected by SRT2104 and CR, respectively, of which 37 gene
sets were shared. Interestingly, ~32% (12/37) of these pathways were
downregulated by both interventions, while ~65% (24/37) were recip-
rocally altered by CR and SRT2104 (Fig. 2D). The complete list of
overlapping gene sets is presented in Table S6 (liver) and Table S7
(muscle). Among the gene sets thatweremodified in the same direction in
liver included ‘Ribosomal_proteins’ and ‘Ceramide_Pathway’, whereas
reciprocal regulation of gene sets by CR and SRT2104 in muscle included
‘Boquest_CD31plus_vs_CD31minus_Up’, ‘Stemcell_Neural_Up’, and
‘Iglesias_E2Fminus_Up’ (Fig 2E). Resident muscle stem cell side popula-
tion as defined as CD31 (Pecam-1) negative lineage (Motohashi et al.,
2008) might be reciprocally affected by SRT2104 or CR (Schmuck et al.,
2011).
The effect of SRT2104 resulted in an overall downregulation of
inflammatory pathways in the muscle, while being more complex in the
liver. Nevertheless, the expression profile of several genes controlled by
the pro-inflammatory NF-jB transcription factor exhibited a pattern that
was largely comparable between SRT2104 and CR treatment in liver
(Table S8) and muscle (Table S9). As anticipated, SRT2104 supplemen-
tation significantly lowered serum TNF-a and MCP-1 levels as compared
to controls (6.1  0.7 vs. 3.9  0.5 and 72.0  8.9 vs. 47.9  8.9 pg
mL1, respectively; P < 0.05).
Intriguingly, a reciprocal pattern of expression of genes related to
mitochondrial metabolism was observed between the liver and muscle,
indicating that the effects of SRT2104 were tissue-specific. In agreement
with the microarray data, transmission electron microscopy revealed
higher mitochondrial content in the liver of SRT2104-fed mice (Fig. 3A),
which correlated with increased citrate synthase activity (Fig. 3B). In
contrast, mitochondrial size was significantly higher in muscle of
SRT2104-fed mice despite no change in citrate synthase activity
(Fig. 3A,B). In both liver and muscle, expression of subunits of ETC
protein complexes was either unaltered or slightly downregulated after
SRT2104 treatment (Fig. S2).
The anti-inflammatory effects of SRT2104 that were observed in SD-
fed mice correlated with defect in NF-jB-induced gene expression (Table
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S8). The ratio of phospho-active to total form of RelA/p65 fell in the
muscle of SRT2104-treated mice, while being unaffected in the liver of
these animals (Fig. 3C). This reduction in ‘active’ NF-jB coincided with
significant increase in IjBa levels (Fig. 3C). A critical mechanism of
transcriptional suppression of NF-jB involves the copper metabolism
MURR1 domain containing (COMMD) proteins through promotion of the
ubiquitination and degradation of NF-jB subunits (Maine et al., 2007).
Analysis of COMMD gene expression revealed a significant increase in the
mRNA levels of COMMD1 and COMMD10 in muscle, but not in liver, of
SRT2104-treated mice compared with control SD-fed mice (Fig. 3D).
RelA/p65 protein levels were upregulated in C2C12myoblasts in response
to SRT2104 treatment (Fig. S3), in agreement with the increased
expression of RelA/p65 in muscle of SRT2104-treated mice (Fig. 3C).
The transactivation potential of NF-jB is modulated by phosphorylation
and acetylation (Hayden & Ghosh, 2008) whereby Sirt1-mediated
deacetylation of RelA/p65 causes a decrease in NF-jB transcriptional
activity (Yeung et al., 2004). Here, SRT2104 led to lower acetylation of
RelA/p65 in C2C12myoblasts (Fig. S3), likely due to selective activation of
SIRT1 (Hubbard et al., 2013). These findings together with the microarray
data suggest that SRT2104 suppresses NF-jB activity partly through
increase in COMMD expression and reduction in RelA/p65 acetylation.
Oxidative stress activates NF-jB, while SIRT1 activation increases the
antioxidant response (Salminen et al., 2013). Here, protein carbonylation
and formation of 4-HNE adduct, a marker of lipid peroxidation, were
significantly reduced in the liver and muscle of SRT2104-treated mice,
with the effect being more pronounced in muscle (Fig. 3E). The levels of
the antioxidant protein superoxide dismutase (SOD2) were unchanged in
the liver, but increased in muscles of SRT2104-treated animals (Fig. 3E).
The antioxidant capacity of SRT2104 may represent a compensatory
stress signal triggered in response to age-dependent, ROS-mediated
mitochondrial dysfunction in mice, with a predominant effect of
SRT2104 on mitochondria of skeletal muscle. This adaptive response
called mitochondrial hormesis has been found to promote longevity in
Drosophila (Owusu-Ansah et al., 2013).
(A)
(D) (E)
(B) (C)
Fig. 2 SRT2104 changes the gene expression profile differently in liver and muscle. (A) Principal component analysis (PCA) was performed on liver and muscles tissues of
mice fed a SD or SD supplemented with SRT2104. (B) Parametric analysis of gene-set enrichment (PAGE) analysis was performed on microarray data from mice fed a SD or
subjected to SRT2104. Columns show pathways significantly upregulated (red) or downregulated (blue) by SRT2104 treatment. See also Tables S5–S7. (C) Effect of SRT2104
on inflammatory and mitochondrial-related pathways from the PAGE analysis for liver and skeletal muscle. (D) Venn diagrams of overlapping gene sets significantly modified
by SRT2104 vs. calorie restriction (CR). Upregulated gene sets are depicted in red and the downregulated gene sets in blue. (E) Effect of SRT2104 and CR on select gene sets
from mouse liver and muscle. The list of the significantly modified gene sets can be found in Tables S6 and S7. SD, standard diet.
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Short-term SRT2104 treatment preserves muscle and bone
mass
Short-term effects of SRT2104 were examined using the hindlimb
suspension, a well-established model of muscle atrophy (Sandri et al.,
2004). SRT2104 supplementation did not affect bodyweights or food
consumption during 2 weeks of unloading (Fig. 4A). However, the
induced loss of muscle mass for both the soleus and gastrocnemius
muscles was attenuated in the SRT2104 cohort (Fig. 4B). Using a second
model of atrophy, where endocrine signals rather than inactivity promote
muscle loss, both the soleus and tibialis muscles from SRT2104-treated
mice were found to be more resistant to fasting-induced atrophy (Fig.
S4A). The involvement of NF-jB in the control of muscle size and strength
(Cai et al., 2004;Mourkioti et al., 2006) and the ability of SIRT1 activators
to attenuate NF-jB signaling led us to examine expression of pro-
inflammatory mediators and RelA/p65 levels following short-term sup-
plementation with SRT2104. Using the hindlimb-unloading model,
SRT2104 treatment did not affect RelA/p65 protein levels, but led to an
increase in PGC-1a levels (Fig. S4B). The latter observation may partly
explain the protection against muscle atrophy through suppression of
FOXO3-mediated induction of the atrogenes MuRF-1 and atrogin-1
(Sandri et al., 2006). In addition, AKT is known to suppress FOXO3
transcriptional activity (Milne et al., 2007), although data presented here
do not show alterations in pAKT protein levels after SRT2104 treatment
(Fig. S4B). To further elucidate the role of SIRT1 in muscle atrophy, young
transgenic mice with muscle-specific SIRT1 knock-down (mSIRT1KO)
were subjected to 2 weeks of hindlimb suspension.When compared with
wild-type animals, suspended mSIRT1KO mice exhibited a significant
increase in skeletal muscle atrophy (Fig. S4C). These results indicate that
SIRT1 activation via short-term supplementation with SRT2104 alleviates
muscle loss in hindlimb-unloading model in mice.
Unloading is also known to cause disuse osteoporosis (Sandri et al.,
2004). SRT2104-treated mice subjected to hindlimb suspension had
higher trabecular bone volume, trabecular connectivity, and trabecular
bone mineral density, but not cortical bone mass (data not shown),
compared with the SD-fed control mice (Fig. S4C). To better evaluate the
specificity of SRT2104 action, C2C12 myoblasts were stably transfected
with small hairpin RNA to knock-down SIRT1 and then examined for
alkaline phosphatase (AP) activity, a marker for osteogenic differentia-
tion. The ability of SRT2104 to increase AP activity was totally dependent
on SIRT1 expression (Fig. 4D). Similarly, the proliferation rate was
markedly reduced after SRT2104 treatment of C2C12 myoblasts (Fig.
S4D). In a second series of experiments, mineralization in bone marrow-
derived osteoblastic cells was increased, while the number of osteoclasts
was decreased upon treatment of wild-type mice with SRT2104 (Fig. S4E
and Fig. 4E). This action of SRT2104 was not observed in cells derived
from mice lacking SIRT1 (SIRT1f/f) (Fig. 4E). The role of SIRT1 in bone
remodeling was further confirmed in whole-body SIRT1KO mice showing
reduced cortical bone thickness compared with wild-type mice (Fig. 4F).
This is in agreement with previous reports showing the beneficial role of
SIRT1 in regulating bone mass (Cohen-Kfir et al., 2011; Edwards et al.,
2013). Thus, SRT2104 affects both features of age-related osteoporosis
(A) (B)
(D)(C)
(E)
Fig. 3 SRT2104 treatment increases mitochondrial content and suppresses the inflammatory response. (A) Representative transmission electron micrographs of liver and
muscle, and the respective mitochondrial quantification. (B) Citrate synthase activity. (C) Representative immunoblots from inflammatory markers in liver and muscle tissues.
(D) mRNA levels of COMMD genes assessed by quantitative real-time PCR. Relative expression values were normalized to SD-fed mice. (E) Representative immunoblots from
oxidative stress markers in liver and muscles. Data are shown as mean  SEM. *P < 0.05 compared with SD-fed mice.
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by increasing bone formation and suppressing bone resorption in a
SIRT1-dependent manner.
We acknowledge the limitations of using male mice only, and the fact
that some experiments involved small numbers of animals. Nevertheless,
we provide novel evidence for the beneficial effects of SIRT1 activators
on healthspan and lifespan in male mice maintained on standard diet.
Moreover, SRT2104 may have therapeutic utility against sarcopenia and
involutional and disuse-mediated osteoporosis.
Experimental procedures
Longevity study animals
Male C57BL/6J mice were obtained from the Jackson Laboratory (Bar
Harbor, ME, USA) and housed at the Gerontology Research Center
(Baltimore, MD, USA). Mice were housed in cages of four with ad libitum
access to diet and tap water. Mice were electronically tagged for
identification (Biomedic Data System Inc., Maywood, NJ, USA), and
bodyweight and food intake were monitored twice monthly. Mice were
not fasted prior to sacrifice. Animal rooms were maintained at 20–22 °C
with 30–70% relative humidity and a 12-hour light/dark cycle. All animal
protocols were approved by the Animal Care and Use Committee (325-
LEG-2012) of the National Institute on Aging.
Generation of a whole-body SIRT1 knockout mouse
Mice harboring a Cre-ERT2 fusion protein were crossed to SIRT1Dex4
mice (Cheng et al., 2003) to generate SIRT1Dex4ERT2 mice in which the
catalytic region of SIRT1 can be deleted upon treatment with tamoxifen,
as described previously (Price et al., 2012). Cre induction was carried out
by i.p. injection of tamoxifen citrate (1 mg mouse1 per day) for 5 days.
Mice were not fasted prior to sacrifice. Western blots have been
performed to confirm successful reduction in SIRT1 protein expression in
whole-body SIRT1-KO mice (Price et al., 2012).
Generation of a muscle-specific adult-inducible SIRT1
knockout mouse
An adult-inducible muscle-specific SIRT1 knockout mouse was gener-
ated by crossing mice with a Cre recombinase transgene under the
control of the human skeletal actin promoter (HSA-Cre) with SIRT1Dex4
mice. Cre induction was carried out by i.p. injection with tamoxifen
citrate (1 mg mouse1 per day) for 5 days. Mice were not fasted prior
to sacrifice. Deletion of SIRT1 was confirmed by Western blotting (data
not shown).
Hindlimb suspension study
At 5 months of age, mice were housed individually and suspended by the
tail using a strip of adhesive surgical tape attached to a nylon
monofilament line via a stainless steel swivel. Mice were suspended at a
30° angle to the floor with only the forelimbs touching the floor. The
swivel enabled the animal to explore the cage (360° range of motion) and
obtain food and water freely. Food consumption and bodyweight were
recorded daily, and the angle of suspension was adjusted if necessary.
Following 14 days of suspension, mice were euthanized and soleus,
plantaris, and gastrocnemius muscles were collected using standardized
dissection methods. Mice were not fasted prior to sacrifice. Muscle tissue
was cleaned of excess fat and connective tissue, weighed on an analytical
balance, and collected for further analysis (n = 10 SD, n = 10 SRT2104,
26 weeks age, 6 weeks diet; muscle-specific SIRT1 knockout (mSIRT1 KO)
mice: n = 10 wild-type, n = 10 mSIRT1 KO, 22 weeks age).
48-h fasting study
Male C57BL/6 mice were obtained from the Jackson Laboratory (Bar
Harbor) at 4 months of age. They were fed house chow (Harlan Teklad
Global 18% Protein Rodent Diet; Harlan Teklad, Madison, WI, USA) until
they reached 7 months of age at which time they were fed either a
standard AIN-93G diet (SD; carbohydrate:protein:fat ratio of 64:19:17
percent of kcal) or SD supplemented with SRT2104 (100 mg kg1) for
6 weeks. Then, mice were moved to clean cages and had food removed
for 48 h. Water was available ad libitum throughout this time. Following
48 h of fasting, mice were euthanized and soleus, plantaris, gastrocne-
mius, tibialis, and extensor digitorum longus were dissected using
standardized dissection methods. Individual muscles were weighed and
frozen for further analysis (n = 7 SD, n = 7 SRT2104; 40 weeks age,
12 weeks diet).
Diets
For the longevity study, diets were started at 28 weeks of age after
randomization into two groups of 100 mice per group. Mice were fed a
standard AIN-93G diet (SD; carbohydrate:protein:fat ratio of 64:19:17
percent of kcal), or a SD supplemented with SRT2104. SRT2104 was
added at a dose of 1.33 g drug per kg of chow, formulated to provide
daily doses of ~ 100 mg drug kg1 bodyweight. The longevity study diets
were purchased from Dyets, Inc. (Bethlehem, PA, USA), and SRT2104, a
proprietary compound, was provided by Sirtris Pharmaceuticals, Inc.
(Cambridge, MA, USA). For the hindlimb suspension study, starting at
4 months of age, C57BL/6 mice were fed either a standard AIN-93G diet
(SD; carbohydrate:protein:fat ratio of 64:19:17 percent of kcal) or a SD
supplemented with SRT2104 for 4 weeks prior to suspension, and then
for an additional 2 weeks during the suspension. Diets were formulated
so mice received a daily dose of 200 mg drug kg1 of bodyweight. Diets
were supplied directly to us by Sirtris Pharmaceuticals, Inc. For the 48-h
fasting study, mice were fed either SD or a SD supplemented with
SRT2104 (100 mg kg1) for 6 weeks prior to sacrifice. This is the same
diet as for the longevity study mice. For the whole-body SIRT1 knockout
and muscle-specific SIRT1 knockout mouse models, mice were main-
tained on house chow (Teklad Global 18% Protein Rodent Diet; Harlan
Teklad; carbohydrate:protein:fat ratio of 58:24:18 percent of kcal) for the
course of their lives.
Survival study
Animals were inspected daily for health issues, and deaths were
recorded for each animal. Moribund animals were euthanized, and
every animal found dead or euthanized was necropsied. Criteria for
euthanasia were based on an independent assessment by a veterinarian
according to the AAALAC guidelines. For the longevity study, only cases
where the condition of the animal was considered incompatible with
continued survival are represented as deaths in the curves. Animals
removed at sacrifice or euthanized due to reasons not related to
incompatible survival were considered as censored deaths. In the
standard diet group, 18 mice were censored due to dermatitis (n = 3;
80 weeks age, 97 weeks age, 112 weeks age), paralysis (n = 1;
37 weeks age), growth per mass (n = 1; 105 weeks age), or exper-
imental procedures (n = 13; 40 weeks age, 115 weeks age), leaving 83
mice for the survival study. Of the 18 mice censored, only five were
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euthanized. In the SRT2104 group, 14 mice were censored due to vets
orders (n = 2; 74 weeks age, 97 weeks age), prolapsed anus (n = 1;
79 weeks age), or experimental procedures (n = 11; 40 weeks age,
115 weeks age), leaving 86 mice for the survival analysis. Of the 14 mice
censored, three were euthanized.
Body composition
Measurements of lean, fat, and fluid mass in live mice were acquired by
nuclear magnetic resonance (NMR) using the Minispec LF90 (Bruker
Optics, Billerica, MA, USA) (n = 15 SD, n = 13 SRT2104; 76 weeks age;
49 weeks diet).
Metabolic assessment
Mouse metabolic rate was assessed by indirect calorimetry in open-circuit
oxymax chambers using the Comprehensive Lab Animal Monitoring
System (CLAMS; Columbus Instruments, Columbus, OH, USA) as
described previously (Minor et al., 2011) (n = 8 SD, n = 8 SRT2104;
56 weeks age, 29 weeks diet).
Physical performance
All mice were acclimated to the testing room for 15 min prior to the
commencement of any testing. Rotarod and treadmill methodologies are
provided in the supplemental materials.
Oral glucose tolerance test (OGTT)
Following an overnight fast, mice received a 30% glucose solution (2 g
kg1 glucose by gavage). Blood glucose was measured using an Ascensia
Elite glucose meter (Bayer, Mishawaka, IN, USA) at 0, 15, 30, 60, and
120 min following gavage (n = 6 SD, n = 8 SRT2104; 73 weeks age;
46 weeks diet).
Insulin tolerance test (ITT)
Followinga3-h fast,mice receivedan i.p. injectionof human insulin (1.5 IU
kg1;NovoNordisk Inc., Plainsboro,NJ,USA).Bloodglucosewasmeasured
using an Ascensia Elite glucosemeter (Bayer) at 0, 15, 30, 60 and 120 min
(n = 4 SD, n = 7 SRT2104; 70 weeks age; 30 weeks diet).
Serum markers and HOMA calculation
Information can be found in the supplemental section.
Histology
Mice were euthanized and organs fixed for histological analysis in 4%
paraformaldehyde. Tissues were embedded in paraffin and stained with
hematoxylin and eosin. Pathology was scored by a qualified pathologist
blinded to diet and treatment group (n = 6 SD, n = 6 SRT2104;
81 weeks age, 41 weeks diet).
(A)
(C)
(D) (E) (F)
(B)
Fig. 4 Short-term SRT2104 treatment preserves muscle and bone mass. (A) Bodyweights during 14 days of hindlimb suspension and average food consumption (inset) for
6-month-old mice fed either a standard diet (SD) or SD supplemented with SRT2104 for 6 weeks. (B) Muscle weights. (C) Trabecular bone volume, trabecular connectivity,
and trabecular bone mineral density (BMD). (D) Alkaline phosphatase (AP) activity in C2C12 cells infected with SIRT1 shRNA or nontargeting shRNA control and treated with
1 and 3 lM SRT2104 for 24 h. (E) Osteoclast (OC) number in bone marrow-derived osteoblastic cells from wild-type (WT) mice and SIRT1f/f mice and treated with 1 and 3 lM
SRT2104 for 4 days. (F) Cortical thickness in femurs from wild-type (WT) and SIRT1KO mice. Data are mean  SEM. *P < 0.05. SOL, soleus; PL, plantaris; GAS,
gastrocnemius; BV, bone volume; TV, total volume; Tb, trabecular.
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Electron microscopy
Liver and skeletal muscle (gastrocnemius) from mice were removed and
placed directly into a fixative solution consisting of 2.5% glutaraldehyde
and 3% paraformaldehyde in 0.1 M sodium cacodylate buffer (Electron
Microscopy Sciences, Hatfield, PA, USA). Additional information can be
found in the supplemental materials (n = 3 SD, n = 3 SRT2104;
81 weeks age, 41 weeks diet).
Microarray
Principal components were calculated using DIANE 6.0 software (http://
www.grc.nia.nih.gov/branches/rrb/dna/diane_software.pdf). For the cal-
culation of pairwise distances between samples, each microarray was
considered as a point in a high-dimensional space because we treated
each probe as a variable. Parametric analysis of gene-set enrichment
(PAGE) was analyzed as previously described (Kim & Volsky, 2005). All
raw data are available in the Gene Expression Omnibus database
(Accession No. GSE49000) (n = 4–5 per group; 41 weeks age,
14 weeks diet).
PCR
Detailed information can be found in the supplemental section.
Western blotting
Detailed information can be found in the supplemental section.
Citrate synthase activity
Citrate synthase activity was determined in ~20 lg of protein lysates
following the method described by Bernier et al. (2011). Citrate synthase
were determined using spectrophotometric methods. Results were
expressed in nmol mg1 protein per min (n = 6 SD, n = 6 SRT2104;
81 weeks age, 41 weeks diet).
C2C12 cell culture conditions and treatment
C2C12 cell line (ATCC, Manassas, VA, USA) was cultured in low glucose
Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen, Carlsbad, CA,
USA) supplemented with 10% fetal bovine serum (FBS; Invitrogen) and
penicillin–streptomycin (Invitrogen). Cells were treated with vehicle
(0.1% DMSO) or 3 lM SRT2104 for 24 h and then harvested for protein
and Western blotting using methods detailed elsewhere.
Bone imaging
Femurs were loaded into 10 mm diameter scanning tubes and imaged
with a Scanco microCT40 instrument (CT40, Scanco Biomedical,
Bruttisellen, Switzerland) as previously described (Jilka et al., 2010;
Martin-Millan et al., 2010). Cortical and trabecular bone measurements
were analyzed as previously described (Martin-Millan et al., 2010; Onal
et al., 2012). Additional information can be found in the supplemental
section.
Osteoclast formation and adenovirus infection
Macrophages were developed from bone marrow cells flushed from the
femurs of three wild-type or SIRT1f/f mice (Jackson Laboratories, Bar Harbor,
ME, USA) cultured in a-MEM supplemented with 10% FBS and 1% PSG
(Invitrogen) in the presence of 30 ng mL1 M-CSF (R&D Systems,
Minneapolis, MN, USA). Four days later, cells were infected with adenovirus
encoding Cre recombinase (Ad-Cre) (Vector Biolabs, Philadelphia, PA, USA)
at a MOI of 30 for 6 h. Seventy-two hours later, cells were trypsinized and
replated in 48-well plates and cultured for 4 days with 30 ng mL1 M-CSF
and 30 ng mL1 RANKL (R&D Systems) to obtain osteoclasts, in the
presence of vehicle or SRT2104. At the end of the experiment, osteoclasts
were fixed with 10% neutral-buffered formalin for 15 min and stained for
tartrate-resistant acid phosphatase (TRAP). Multinuclear TRAP+ cells were
quantified.
Alkaline phosphatase (AP) activity and SIRT1 silencing
C2C12 cells were cultured in DMEM supplemented with 10% FBS, 1%
each penicillin, streptomycin, and glutamine, and 1% sodium pyruvate.
Expression of SIRT1 was knocked down by transduction with lentiviruses
encoding shRNA to Sirt1 (NM_019812) according to the manufacturer’s
protocol (Sigma-Aldrich, St. Louis, MO, USA). C2C12 cells transduced
with a nontarget shRNA (SHC002V) were used as control. After selection
with puromycin (2500 ng mL1) for 14 days, the SIRT1-silenced cells
were seeded at 2 9 104 cm2 in medium containing 10% FBS. The
following day, the medium was replaced with 5% serum-containing
medium. Cells were lysed in 100 mM glycine, 1 mMMgCl2, and 1% Triton
X-100 at pH 10. AP activity in cell lysates was determined using a buffer
containing 2-amino-2-methylpropanol and p-nitrophenylphosphate
(Sigma-Aldrich). Alkaline phosphatase activity was normalized to protein
content, which was determined using a Bio-Rad DC protein assay kit
(Hercules, CA, USA).
Mineralization assay
Detailed information can be found in the supplemental section.
Proliferation assay
Detailed information can be found in the supplemental section.
Statistics
Data are expressed as means  standard error of the mean (SEM).
Student’s t-tests were used for all comparisons. Mortality during the
survival study was assessed through the use of the log-rank test to
compare the differences in Kaplan–Meier survival curves. Maximal
lifespan was defined as the 10th percentile of mice still alive. Analyses
were performed using Excel 2010 (Microsoft Corp., Redmond, WA,
USA), IBM SPSS Statistics (Amonk, NY, USA), or SIGMASTAT 3.0 (Aspire
Software International, Ashburn, VA, USA). A P value of ≤ 0.05 was
considered statistically significant.
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